Inactive Instrument

Highlights Elite Pharmaceuticals, Inc. Other OTC

Equities

ELTP

US28659T2006

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Elite Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 14	CI
Elite Pharmaceuticals, Inc. Files ANDA with US FDA to Market Central Nervous System Stimulant	Dec. 26	CI
Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR to Marketing Partner Prasco, LLC	Dec. 12	CI
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 14	CI
Elite Pharmaceuticals Files Anda with US FDA to Market Opiate Analgesic Product	23-09-25	CI
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study	23-08-28	CI
Elite Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14	CI
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-06-29	CI
Elite Pharmaceuticals Files ANDA with US FDA to Market Antimetabolite Product	23-04-20	CI
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
Elite Pharmaceuticals Reports Positive Results from A Pivotal Bioequivalence Study	23-02-07	CI
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-14	CI
Elite Pharmaceuticals Inc. and Lannett Company, Inc. Jointly Terminated the License, Supply and Distribution Agreement for Vigabatrin	22-11-10	CI
Elite Pharmaceuticals Inc. Receives Notification from Lannett Company, Inc. for Terminating the License, Supply and Distribution Agreement	22-08-26	CI
Elite Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-15	CI
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	22-06-29	CI
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-14	CI
Elite Pharmaceuticals Inc. Signs License and Distribution Agreement with Dexcel Ltd	21-12-09	CI
Elite Pharmaceuticals, Inc. Renews Its License, Supply, and Distribution Agreement with Lannett Company, Inc	21-12-02	CI
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Elite Pharmaceuticals, Inc. Other OTC

Equities

ELTP

US28659T2006

Highlights

Filters